| Name | Title | Contact Details |
|---|
DBV Technologies (DBV) is a clinical-stage biopharmaceutical company focused on discovering safe and effective treatments for patients with food allergies and other unmet medical needs. DBV has developed a proprietary technology platform called Viaskin®, which is based on epicutaneous immunotherapy, or EPIT®, DBV`s method of delivering biologically active compounds to the immune system. This novel mechanism of action accesses the immune system through intact skin without allowing passage of the antigen into the bloodstream. The company is also exploring Viaskin® in other areas of unmet need including vaccines, inflammatory conditions and autoimmune diseases. DBV was founded in 2002 by Dr. Pierre-Henri Benhamou, Chairman and CEO, Dr. Christophe Dupont, Chairman of DBV`s Scientific Advisory Board, and Mr. Bertrand Dupont, Chief Technology Officer.
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Gilson is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Welcome to AB Scientific. Suppliers of innovative products to Pharmaceutical, Clinical and Life Science laboratories in the UK and Ireland.
Access Biologicals is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.